Advertisement
U.S. markets closed
  • S&P Futures

    5,088.75
    -1.25 (-0.02%)
     
  • Dow Futures

    38,984.00
    -32.00 (-0.08%)
     
  • Nasdaq Futures

    18,009.75
    -11.25 (-0.06%)
     
  • Russell 2000 Futures

    2,057.00
    -2.90 (-0.14%)
     
  • Crude Oil

    78.55
    -0.32 (-0.41%)
     
  • Gold

    2,041.20
    -2.90 (-0.14%)
     
  • Silver

    22.47
    -0.06 (-0.28%)
     
  • EUR/USD

    1.0842
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    4.3150
    +0.0160 (+0.37%)
     
  • Vix

    13.43
    -0.31 (-2.26%)
     
  • GBP/USD

    1.2674
    -0.0013 (-0.10%)
     
  • USD/JPY

    150.4060
    -0.0740 (-0.05%)
     
  • Bitcoin USD

    56,933.00
    +529.39 (+0.94%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,683.02
    -1.28 (-0.02%)
     
  • Nikkei 225

    39,118.44
    -121.08 (-0.31%)
     

Cocrystal Pharma Stock Gains After Laying Out Plans To Launch Another COVID-19 Antiviral Candidate

  • Cocrystal Pharma Inc (NASDAQ: COCP) has announced progress on its COVID-19 antiviral drug candidates that target coronaviruses, including SARS-CoV-2, and it also plans to launch a second COVID-19 program with additional antiviral compounds for development, apart from CDI-45205.

  • The company said that it had designed new chemical scaffolds to improve in vitro potency and pharmacokinetic properties. Lead discovery and optimization are ongoing.

  • Identification of another SARS-CoV-2 preclinical lead for oral administration is anticipated this year.

  • Additionally, the company is also developing novel SARS-CoV-2 inhibitors that block viral replication and transcription.

  • In December last year, Cocrystal selected CDI-45205 as its lead coronavirus development candidate, obtained under an exclusive license agreement with Kansas State University Research Foundation (KSURF).

  • CDI-45205 showed good bioavailability in mouse and rat pharmacokinetic studies via intraperitoneal injection and no cytotoxicity against various human cell lines. The company recently demonstrated a strong synergistic effect with the FDA-approved COVID-19 medicine remdesivir.

  • Additionally, a proof-of-concept animal study demonstrated that daily injection of CDI-45205 exhibited favorable in vivo efficacy in MERS-CoV-2 infected mice.

  • Price Action: COCP shares are up 0.85% at $1.19 on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement